Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 6/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995774 | 0.80 | HPGD (0.50) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL706407 | 0.79 | TSHR (0.63) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL30980818 | 0.79 | TSHR (0.63) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL14523045 | 0.79 | KMT2A (0.51) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL19956152 | 0.79 | KMT2A (0.51) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL8989513 | 0.79 | KMT2A (0.56) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL13064450 | 0.79 | KMT2A (0.47) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL11351938 | 0.78 | MAPT (0.69) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL2737128 | 0.76 | TSHR (0.51) | KMT2ATSHRSMN1; SMN2HPGDTHRB | |
| SCHEMBL3370461 | 0.76 | HPGD (0.67) | KMT2ATSHRSMN1; SMN2HPGDTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280970-B1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8124636-B2 | Imidazolidinone derivatives as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2280970-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009132986-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-11-05 | — | — | US | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HSD11B1, HSD17B1, HSD17B11 | KMT2A 2297/4885TSHR 1734/4885SMN1; SMN2 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.